Name: NEUROCRINE BIOSCIENCES INC (NBIX) Stock
Brand: NEUROCRINE BIOSCIENCES INC
Rating: 8.5 (3 reviews)

NBIX Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with Bullish Technical Setup

4 days ago - By: The Motley Fool - Mentions: HNGE CAI XENE CGON ...

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock

4 days ago - By: The Motley Fool - Mentions: ACAD CAI XENE CGON ...

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

11 days ago - By: Zacks Investment Research

Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now

12 days ago - By: Investor's Business Daily - Mentions: RY RY.CA NVO TEVA ...

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied

18 days ago - By: Neurocrine Biosciences, Inc.

Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules

a month ago - By: Neurocrine Biosciences, Inc.

Neurocrine Biosciences to Present at Upcoming Investor Conferences

a month ago - By: Zacks Investment Research

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice

a month ago - By: Neurocrine Biosciences, Inc.

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder

a month ago - By: Zacks Investment Research

Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain?

a month ago - By: Zacks Investment Research

What Makes Neurocrine (NBIX) a New Strong Buy Stock

a month ago - By: Zacks Investment Research - Mentions: BEAM FOLD XENE

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus

a month ago - By: Investor's Business Daily

Neurocrine Bio Surges After Crushing Third-Quarter Expectations

a month ago - By: Neurocrine Biosciences, Inc.

Neurocrine Biosciences Reports Third Quarter 2025 Financial Results

a month ago - By: Benzinga

Examining the Future: Neurocrine Biosciences's Earnings Outlook

a month ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice

2 months ago - By: Zacks Investment Research

3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)

2 months ago - By: Benzinga

What 13 Analyst Ratings Have To Say About Neurocrine Biosciences

2 months ago - By: Neurocrine Biosciences, Inc.

Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules

2 months ago - By: Neurocrine Biosciences, Inc.

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results

2 months ago - By: Neurocrine Biosciences, Inc.

Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise

2 months ago - By: Neurocrine Biosciences, Inc.

Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

3 months ago - By: Neurocrine Biosciences, Inc.

Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden

NEUROCRINE BIOSCIENCES INC (NBIX) Stock News

NBIX Latest News, Press Relases and Analysis